Abstract
Bristol-Myers Squibb is involved in the research and development of treatments
for conditions such as heart disease, high blood pressure, stroke, diabetes,
cancer, HIV/AIDS, depression, schizophrenia and pain. This report provides a
full review of the company's activities together with sales forecasts for key
products to 2010.
Headquartered in New York, Bristol-Myers Squibb (BMS) is involved in the
research and development of treatments for conditions such as heart disease,
high blood pressure, stroke, diabetes, cancer, HIV/AIDS, depression,
schizophrenia and pain. The company's research and development efforts are
principally focused on Oncology, Affective (Psychiatric) Disorders and
Metabolics.
Current Growth Drivers
- Plavix (clopidogrel), a platelet aggregation inhibitor, is BMS' largest
selling product and continues to make substantial year-on-year sales growth.
The product benefits from co-development and co-commercialisation with
sanofi-aventis in a number of markets worldwide. Since its first approval in
1997, Plavix has been prescribed for around 48 million patients.
- Similarly, Avapro/Avalide (irbesartan), an angiotensin II receptor agonist
indicated for the treatment of hypertension and diabetic neuropathy, was
co-developed and co-marketed with sanofi-aventis in several markets and also
has demonstrated steady market gains since its launch.
- Abilify (aripiprazole), indicated for the treatment of schizophrenia and
related conditions, is the company's flagship Affective Disorders product. The
product was licensed from Otsuka, with whom BMS co-promotes Abilify in several
markets, and has made strong sales increases since it became part of BMS'
product portfolio.
- Erbitux (cetuximab) was licensed from ImClone Systems to become BMS' first
biological product. It is used in the treatments of various cancers and in
March 2006, it became the first new treatment for squamous cell head and neck
cancer in nearly three decades.
- Reyataz (atazanavir), a potent azapeptide inhibitor of HIV protease, is
the first once-daily protease inhibitor to be approved by the FDA. In 2005, it
demonstrated the most significant growth of BMS' pharmaceutical products, with
sales increasing by nearly 70 per cent from the previous year.
View Cart
